Future success will require: (1) Combinatorial strategies concurrently targeting NETs and complementary pathogenic pathways (e.g., MMPs, cytokine networks, renin-angiotensin signaling), (2) Prioritization of interventions for established aneurysms rather than prevention-only paradigms, and (3) Identification of NET-driven patient endotypes (e.g., high-CitH3 phenotypes, rapid progressors) to enable personalized therapeutic stratification. The gene discussed is REN; the disease is aneurysm.